Related Experiment Video
Updated: Jul 18, 2025
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse
Naoto Okada1, Takahiro Niimura2, Atsuyuki Saisyo1
1Pharmacy Department, Yamaguchi University Hospital, Yamaguchi, Japan.
Background:
Eosinophilic pneumonia (EP) is a rare adverse event caused by several types of drugs, such as antibiotics; however, its characteristics remain poorly described. This study aimed to analyze the disproportionality between the occurrence of EP and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents and to characterize anti-MRSA agent-induced EP events using the Food and Drug Administration Adverse Event Reporting System (FAERS).
Method:
Disproportionality linking EP and anti-MRSA agents was analyzed through bayesian confidence propagation neural networks of information components and reporting odds ratio methodologies. The FAERS data set for the fourth quarter of 2012 to the fourth quarter of 2022 was used. We also analyzed the characteristics of EP induced by anti-MRSA agents.
Results:
A total of 14 805 795 reports were obtained from FAERS. Disproportionality analysis revealed that the EP signal was detected only in cases with the administration of daptomycin (DAP). This disproportionality signal was consistently detected in the sensitivity analysis. When compared with other reports of DAP-related adverse events, the reports of DAP-related EP were characterized by male sex (odds ratio [OR], 1.94; 95% CI, 1.12-3.37), older age (>70 years; OR, 2.70; 95% CI, 1.68-4.33), and longer duration of treatment (>21 days; OR, 5.08; 95% CI, 3.21-8.05).
Conclusions:
This study revealed that among the anti-MRSA agents, disproportionality in the occurrence of EP was observed only with DAP. Our results suggest that sex, age, and treatment duration may affect the occurrence of DAP-induced EP. Clinicians should exercise caution regarding EP during DAP administration.
Insights
Eosinophilic pneumonia (EP) is a rare adverse event linked to anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) drugs. Daptomycin (DAP) was the only anti-MRSA agent showing a disproportionality signal for EP, particularly in older males with longer treatment durations.
Area of Science:
- Pharmacovigilance
- Pulmonology
- Infectious Diseases
Background:
- Eosinophilic pneumonia (EP) is a rare adverse drug event with poorly understood characteristics.
- This study focuses on adverse events associated with anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents.
Purpose of the Study:
- To analyze the disproportionality between EP occurrence and anti-MRSA agents.
- To characterize EP events induced by anti-MRSA agents using the FAERS database.
Main Methods:
- Bayesian confidence propagation neural networks and reporting odds ratio methodologies were used for disproportionality analysis.
- The Food and Drug Administration Adverse Event Reporting System (FAERS) database from Q4 2012 to Q4 2022 was utilized.
- Characteristics of EP induced by anti-MRSA agents were analyzed.
Main Results:
- A significant disproportionality signal for EP was detected exclusively with daptomycin (DAP) among anti-MRSA agents.
- Daptomycin-related EP cases were associated with male sex (OR 1.94), older age >70 years (OR 2.70), and longer treatment duration >21 days (OR 5.08).
- Sensitivity analysis confirmed the robustness of the EP signal for DAP.
Conclusions:
- Daptomycin is identified as the sole anti-MRSA agent with a disproportionality signal for eosinophilic pneumonia.
- Male sex, advanced age, and extended treatment duration are potential risk factors for DAP-induced EP.
- Clinicians should maintain vigilance for EP during daptomycin therapy.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Drug Regulation
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...